Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach

Research output: Contribution to journalShort survey

9 Citations (Scopus)

Abstract

Extramammary Paget's disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; however, upon becoming invasive, it promptly and frequently metastasizes to regional lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy regimens have been used to treat metastatic EMPD; however, they present limited effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and translational investigative research has elucidated factors and molecular mechanisms underlying the promotion of metastasis, which can lead to targeted therapy-based emerging treatment strategies. Here, we aim to discuss current therapies and their limitations; advancements in illustrating mechanisms promoting invasion, migration, and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic EMPD that may enhance clinical outcomes.

Original languageEnglish
Article number38
JournalFrontiers in Oncology
Volume8
Issue numberFEB
DOIs
Publication statusPublished - 2018 Feb 16

Fingerprint

Extramammary Paget's Disease
Neoplasm Metastasis
Therapeutics
Axilla
Translational Medical Research
Carcinoma in Situ
Human Mammary Glands
Adenocarcinoma
Lymph Nodes
Drug Therapy
Skin
Neoplasms

Keywords

  • Anti-PD-1 antibody
  • CD163M2 macrophage
  • CXCR4-stromal cell-derived factor-1 axis
  • HER2-PI3K/ERK signaling
  • Lymphangiogenesis
  • Metastatic extramammary Paget's disease
  • Mismatch-repair deficient
  • Receptor activator of nuclear factor kappa-B ligand-RANK signaling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Metastatic extramammary Paget's disease : Pathogenesis and novel therapeutic approach. / Fukuda, Keitaro; Funakoshi, Takeru.

In: Frontiers in Oncology, Vol. 8, No. FEB, 38, 16.02.2018.

Research output: Contribution to journalShort survey

@article{af70620429f743dd9294f2fa70d16837,
title = "Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach",
abstract = "Extramammary Paget's disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; however, upon becoming invasive, it promptly and frequently metastasizes to regional lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy regimens have been used to treat metastatic EMPD; however, they present limited effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and translational investigative research has elucidated factors and molecular mechanisms underlying the promotion of metastasis, which can lead to targeted therapy-based emerging treatment strategies. Here, we aim to discuss current therapies and their limitations; advancements in illustrating mechanisms promoting invasion, migration, and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic EMPD that may enhance clinical outcomes.",
keywords = "Anti-PD-1 antibody, CD163M2 macrophage, CXCR4-stromal cell-derived factor-1 axis, HER2-PI3K/ERK signaling, Lymphangiogenesis, Metastatic extramammary Paget's disease, Mismatch-repair deficient, Receptor activator of nuclear factor kappa-B ligand-RANK signaling",
author = "Keitaro Fukuda and Takeru Funakoshi",
year = "2018",
month = "2",
day = "16",
doi = "10.3389/fonc.2018.00038",
language = "English",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Metastatic extramammary Paget's disease

T2 - Pathogenesis and novel therapeutic approach

AU - Fukuda, Keitaro

AU - Funakoshi, Takeru

PY - 2018/2/16

Y1 - 2018/2/16

N2 - Extramammary Paget's disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; however, upon becoming invasive, it promptly and frequently metastasizes to regional lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy regimens have been used to treat metastatic EMPD; however, they present limited effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and translational investigative research has elucidated factors and molecular mechanisms underlying the promotion of metastasis, which can lead to targeted therapy-based emerging treatment strategies. Here, we aim to discuss current therapies and their limitations; advancements in illustrating mechanisms promoting invasion, migration, and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic EMPD that may enhance clinical outcomes.

AB - Extramammary Paget's disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; however, upon becoming invasive, it promptly and frequently metastasizes to regional lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy regimens have been used to treat metastatic EMPD; however, they present limited effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and translational investigative research has elucidated factors and molecular mechanisms underlying the promotion of metastasis, which can lead to targeted therapy-based emerging treatment strategies. Here, we aim to discuss current therapies and their limitations; advancements in illustrating mechanisms promoting invasion, migration, and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic EMPD that may enhance clinical outcomes.

KW - Anti-PD-1 antibody

KW - CD163M2 macrophage

KW - CXCR4-stromal cell-derived factor-1 axis

KW - HER2-PI3K/ERK signaling

KW - Lymphangiogenesis

KW - Metastatic extramammary Paget's disease

KW - Mismatch-repair deficient

KW - Receptor activator of nuclear factor kappa-B ligand-RANK signaling

UR - http://www.scopus.com/inward/record.url?scp=85042449252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042449252&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00038

DO - 10.3389/fonc.2018.00038

M3 - Short survey

AN - SCOPUS:85042449252

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - FEB

M1 - 38

ER -